1.Kumanaan kun oo doolar oo COVID-19 ah oo dawooyin Hindi ah ayaa la iibiyay?iska eeg!
Dhawaan, mowduuc ku saabsan "COVID-19 dawooyinka guud ee Hindida waxaa lagu iibiyay kumanaan yuan sanduuqa" ayaa ka soo muuqday liiska raadinta microblog ee caanka ah.Daawooyinka qaar ayaa lagu soo iibiyay magaca Shabakadda Wararka Shiinaha, saamigiina waa la iibiyay, sidaa awgeed waxa lagama maarmaan noqotay in toddobaad ka hor la ballansado.Dhakhaatiirtu waxay xasuusinayaan in daroogooyinka aan lagu iibsan marin aan rasmi ahayn.Intaa waxaa dheer, kooxaha aan khatarta sare lahayn uma baahna inay isticmaalaan COVID-19 dawo afka ah.
Qiimaha asalka ah ee sanduuqa dawooyinka waa 2300 yuan, qiimaha lagu gadanayo Hindiyana waa 1600 yuan
"Hadda amarada si buuxda ayaa loo ballansan yahay."Dhowr wakiil oo Hindi ah oo iibsada daroogada ayaa u sheegay chinanews.com in dawooyinkoodii Pfizer COVID-19 ee afka laga qaato ee Paxlovid ayaa la iibiyay dhawaan.Haddii loo baahdo, kaliya waxay bixin karaan deebaajiga marka hore, alaabtana waxaa la keeni karaa toddobaad gudaheed ugu horrayn, ama bisha soo socota ugu yaraan.
Haddii ereyada "COVID-19 India", "COVID-19 dawooyinka guud" iyo wixii la mid ah ay ku jiraan goobta ganacsiga e-commerce, macaamiishu waxay si dhakhso ah u heli karaan macluumaadka wakiiladan wax iibsiga, laakiin guud ahaan waxay u baahan yihiin inay ku daraan asxaabta WeChat, iyo ka dib u sheeg macluumaadka alaabta gaarka ah iyo shuruudaha iibka.
Daawooyinka guud ee Paxlovid ee ay iibiyaan wakiiladan waxaa ka mid ah Primovir oo ku jirta baakad cagaaran iyo Paxista oo ku jirta baakad buluug ah.Midda hore waxaa soo saartay Atrica, oo ah shirkad Hindi ah, halka kan dambe ay soo saarto Azista, oo hoos timaada shirkadda dawooyinka Hindiya ee Hetero.Waqtigan xaadirka ah, Primovir oo leh baakadaha cagaaran ayaa joojiyay wax soo saarka, kaliya Paxista oo leh baakadaha buluuga ah ayaa weli ku jira iibka.
Mid ka mid ah wakiillada ayaa soo bandhigay in qiimaha boostada booska guduhu uu ahaa 1600 yuan sanduuqii, iyo tan dibadeed ee tooska ah waxay ahayd 1200 yuan sanduuqii, 400 yuan ka jaban.Qiimaha iibka ee Paxlovid ee Shiinaha waa 2300 yuan sanduuqiiba.
Daawooyinkan guud way adagtahay in hadda la gato.Marka loo eego iibsashada wakiilka kor ku xusan, boos celintu waa la aqbali karaa, iyo boostada tooska ah ee Hindiya waxay iman doontaa Shiinaha qiyaastii 15-20 maalmood gudahood.Waxa uu sidoo kale soo jeediyay in qof walba uu iibsan karo 2 sanduuq oo kaliya.
Dhakhaatiirtu waxay xasuusinayaan: Way adagtahay in runta laga sheego beenta.Feejignow
Dhab ahaantii, Paxlovid muddo dheer ayaa loo isticmaali jiray daawaynta caabuqa COVID-19 gudaha Shiinaha, laakiin inta badan waxaa lagu isticmaalaa cisbitaalada qaar ee loo qoondeeyay waxayna u baahan tahay ogolaanshaha dawooyinka dhakhaatiirta.Isbitaalada oo dhan ma haystaan dawada.
Waxaa xusid mudan in qaar ka mid ah dawooyinka guud ee lagu iibiyo ku saleysan komishanka la iibsan karo iyada oo aan xitaa la siin warqad dhakhtar.Marka la eego arrintan, dhakhaatiirta xirfadda leh waxay xasuusinayaan qof walba inuu feejignaado.
"Dhakhaatiirta xirfadleyda ah ahaan, uma doodno iibsashada ku dayashada ajnabiga ah, sababtoo ah way adag tahay in runta laga sheego beenta."Mr.com in qaar ka mid ah bukaanadii uu wareystay ama qoysaskooda ay si gaar ah u iibsadeen wax-is-daba-marin, oo ay ka walaacsan yihiin in ay iibsadaan dawooyin been abuur ah.Waxa uu sheegay in ay adag tahay in la hubiyo tayada dawooyinka guud ee laga keenayo iyo xaaladaha lagu ilaalinayo dawooyinka marka laga soo iibsanayo dawooyinka guud.
Mr.Kooxaha aan khatarta sare lahayn uma baahna inay ku degdegaan inay iibsadaan, waxaana laga yaabaa in xadgudubku keeno caabbinta daroogada.Sidoo kale caafimaad ahaan looma baahna, sababtoo ah bukaanada intooda badan waa asymptomatic ama khafiif, iyo koorsada cudurku waa mid xadidan.
Ayuu u sheegay chinanews.com in, marka la eego xaaladda Shanghai, isbitaallada waaweyn, cosbitaalada loo qoondeeyay COVID-19 iyo xarumaha kale ee caafimaadka guud ahaan waxay leeyihiin qaddar go'an oo ah dawooyinka ka hortagga COVID-19, oo ay adeegsadaan kooxaha khatarta sare leh ee buuxiya tilmaamaha uu ku dhacay COVID-19, si looga hortago cudur daran loona yareeyo heerka dhimashada.
Intaa waxaa dheer, sida laga soo xigtay warbixinnada warbaahinta, shaqaalaha sharcigu waxay xasuusinayaan in Hindiya COVID-19 dawooyinka guud ee lagu iibiyo khadka aan weli laga ansixin Shiinaha.Sida uu dhigayo sharciga Maamulka Dawooyinka ee hadda jira ee Jamhuuriyadda Dadka Shiinaha, in kasta oo dawooyinka lagu taxay dibadda laakiin aan laga ansixin Shiinaha hadda aan si fudud loogu aqoonsan dawooyin been abuur ah, hawl-wadeennada ayaa wali la kulmi doona ciqaab maamul oo soo dejinta sharci-darrada ah ee daroogada.
2.Xinlitai way tagtay!Haysashada laba nooc oo 1 bilyan ah, 11 nooc oo ah nooca 1 ee dawooyinka cusub.
Dhawaan, dhuumaha Xinlitai R&D waxay sameeyeen horumar cusub.Dawooyinka cusub ee fasalka 1-aad ee SAL0133 kaniini ayaa loo dalbaday isticmaalka kiliinikada.Natiijooyinka falanqaynta hordhaca ah ee tirakoobka ayaa laga helay tijaabada caafimaadka ee Wajiga Ib ee PCSK9 monoclonal antibody.Ilaa 2022, Xinlitai waxay IND/NDA ka codsatay 7 dawooyin cusub, cilmi-baadhista iyo horumarinta hal-abuurka ayaa si joogto ah loo dhiirrigeliyay.Waqtigan xaadirka ah, Xinlitai waxay leedahay laba nooc oo 1 bilyan ah, 22 ka mid ah ayaa la qiimeeyay (8 waa kuwa ugu horreeya);21 dawooyin cusub ayaa ku socda cilmi-baaris, 6 ka mid ah waxay ku jiraan marxaladda bukaan-socodka ee NDA ama Wajiga III, iyo dhuumaha hal-abuurka ayaa galay xilliga lacag-bixinta.
Daawaynta afka ee COVID-19 ayaa soo ifbaxday!Xinlitai wuxuu galaa wareegga COVID-19
Diseembar 20, Xinlitai ayaa ku dhawaaqday in codsiga kiliinikada ee SAL0133, oo ah daawo cusub oo molecule yar oo si madax-bannaan u soo saartay shirkadda, ay aqbashay Maamulka Cuntada iyo Dawooyinka ee Gobolka.SAL0133 waa xoog badan, ballaaran-spectrum ka-hortagga novel coronavirus 3CL protease (3CLpro) inhibitor si madax-bannaan u curiyey oo ay horumarisay shirkad leh xuquuqaha lahaanshaha garaadka madaxbannaan.Waqtigan xaadirka ah, tilmaanta bukaan-socod ee la soo saarayo waa in lagu daweeyo dadka qaangaarka ah ee fudud/caadiga ah ee novel coronavirus pneumonia (COVID-19).
3CLpro waxay door muhiim ah ka ciyaartaa taranka RNA ee novel coronavirus, badiyaa marxaladda taranka ee bilawga ah ka dib markii uu fayrasku galo unuga martida loo yahay, isagoo joojinaya waxqabadka 3CLpro protease, kaas oo si wax ku ool ah u xannibi kara taranka fayraska oo gaadhi kara doorka ka hortagga novel coronavirus.
SAL0133 waxay leedahay hannaan ficil oo cad, waxayna leedahay saameyn xooggan oo ballaaran oo ka hortag ah COVID-19.Waxaa la filayaa in aysan u baahnayn in lagu daro CYP3A4 inhibitor ritonavir, iyo khatarta suurtagalka ah ee isdhexgalka daroogada ayaa yar;Waxa la filayaa in la gaadho isticmaalka dawooyinka keliya ee kiliinikada hal mar maalintii oo ay wanaajiso u hoggaansanaanta daawaynta bukaanka.Haddii si guul leh loo horumariyo oo loo oggolaado suuqgeyn, waxay siin doontaa bukaannada doorashooyin cusub oo dawooyin ah si ay u daboolaan baahiyaha caafimaad ee aan la daboolin.
Cilmi-baarista iyo horumarinta 3CL ee la beegsanayo ka-hortagga COVID-19 dawooyinka unugyada yaryar ee afka ayaa soo jiitay dareen ballaaran.Waqtigan xaadirka ah, kaliya Pfizer's Paxlovid ayaa loo oggolaaday suuqgeynta adduunka.In ka badan 10 shirkadood oo dawooyinka gudaha ah iyo machadyada cilmi-baarista sayniska ayaa sameeyay cilmi-baaris iyo horumarin 3CL bartilmaameedka daawooyinka ka hortagga COVID-19, oo ay ku jiraan FB2001 ee Biology Frontier, VV993 ee Junshi Biology/Wangshan Wangshui, SIM0417 ee Pharmaceutical Pioneer, RAY1216 kiniinnada Pharmangsheutical GST-HG171 ee Guangshengtang, iwm.
Iyadoo 1 bilyan oo nooc oo waaweyn ay gacanta ku hayaan, 7 dawooyin cusub ayaa sanadkan soo dhaweynaya horumarka cusub
Dhamaadkii 2022, oo ah wakiilka caadiga ah ee isbeddelka R&D ee warshadaha dawooyinka, Xinlitai waxay si guul leh u heshay dariiqeeda horumarineed ee hal-abuurka leh ee cadaadiska iyo hagaajinta.
Saddexdii rubuc ee hore ee 2022, dakhliga shirkadu waxa uu ahaa 2.548 bilyan yuan, iyada oo kobac sanadeedkiiba ahaa 16.5%, faa’iidada saafiga ahina waxa ay ahayd 539 milyan yuan, iyada oo kobac sanadeedkiiba ahaa 37.64%.Waxqabadka wanaagsan ayaa sees adag u dhigay horumarka xiga.Shirkaddu waxay filaysaa in 2022, Taijia (kiniiniyada clopidogrel bisulfate) ay kasban doonto ilaa 1 bilyan yuan, Sinritan (kiniiniyada alisartan) waxay kasban doontaa qiyaastii 900 milyan yuan ilaa 1 bilyan yuan.Shirkaddu waxay leedahay 22 nooc, 8 ka mid ah waa kuwa ugu horreeya Shiinaha.
2019, kala duwanaanshaha ugu weyn ee Xinlitai, Taijia, ayaa lumiyay dalabkeedii 4+7 isbahaysiga iibka dhexe, kaas oo ku qasbay Xinlitai inuu isbedel sameeyo.Warbixinta sanadlaha ah ee 2019, Xinlitai ayaa ku dhawaaqday in "tuubada cilmi-baarista si istiraatijiyadeed loo hagaajin doono, iyo mashaariicda analooga ah ee bayoolojiga iyo antibiyootiga ee marxaladaha bukaan-socodka qaarkood waa la joojin doonaa".2020, si loo sii wanaajiyo dhuumaha hoos yimaada cilmi baarista iyo diiradda saaraya R&D iyo kor u qaadida alaabada hal-abuurka leh, Xinlitai waxay wareejisay xuquuqaha iyo danaha ku habboon ee dapoxetine hydrochloride, erlotinib hydrochloride, rivasaban iyo mashaariicda kale, waxayna heshay lacag wareejin ah.
Qaar ka mid ah hagaajinta ka dib, wakhtigan xaadirka ah, dhuunta daawada guud ee Xinritai kaliya waxay haysataa arjiga suuqgeynta fasalka 4 ee ku dayashada kiniiniyada sodium Sakubatrovalsartan ee dib u eegista, iyo codsiga dheeriga ah ee qiimeynta joogtada ah ee cefuroxime sodium ee duritaanka iyo cefotaxime sodium ee duritaanka dib u eegis.Waxaa mudan in la xuso in tan iyo Luulyo 2019, Xinlitai ma codsan dawooyin cusub oo cusub in ka badan 3 sano, oo ay sii kordhisay hal-abuurka iyo cilmi-baarista.
Ilaa 2022, Xinlitai waxa ay horumar joogto ah ka samaysay cilmi-baadhista iyo horumarinta dawooyinka hal-abuurka leh.Janaayo 4, 2022, arjiga liiska CINRITAI's HIF-PHI kiniinnada Enasitar inhibitor waxaa qaaday CDE;Intaa ka dib, shirkaddu waxay soo gudbisay codsiyo caafimaad oo loogu talagalay shan dawo oo cusub oo ah fasalka 1, kuwaas oo ah, recombinant human neuromodulin-1 anti HER3 antibody fusion protein injections, SAL0112 tablets, SAL008 injections, SAL0119 tablets and SAL0133 tablets;Noofembar 3, fasalka cusub ee 2.3 ayaa hagaajiyay daroogada alisartan iyo kiniinnada amlodipine ee SINRITAI waxay soo gudbiyeen codsi liis ah, kaas oo la filayo inuu sameeyo is-dhexgal istaraatiijiyadeed oo leh liiska liiska 1.1 ee daawada dhiig-karka ee SINRITAI.
JinDun Medicalwaxay leedahay iskaashi cilmi-baaris cilmiyeed oo muddo-dheer ah iyo ku-tallaalidda tignoolajiyada jaamacadaha Shiinaha.Iyada oo Jiangsu kheyraad caafimaad qani ah, waxay leedahay xiriir ganacsi oo muddo dheer India, Koonfur-bari Asia, South Korea, Japan iyo suuqyada kale.Waxa kale oo ay bixisaa adeegyada suuqa iyo iibka ee geeddi-socodka oo dhan laga bilaabo dhexe ilaa API alaabta dhammaatay.Ka faa'iidayso agabka la ururiyey ee Kiimikada Yangshi ee kimistariga fluorine si aad u bixiso adeegyo gaar ah oo kiimikaad ah oo loogu talagalay lammaanayaasha.Bixi habka hal-abuurka iyo adeegyada cilmi-baarista wasakhaysan si loo beegsado macaamiisha.
JinDun Medical wuxuu ku adkaysanayaa in la abuuro koox leh riyooyin, samaynta alaabooyin leh sharaf, taxadar leh, adag, oo dhan u baxa si ay u noqdaan lammaane la aamini karo iyo saaxiibka macaamiisha! xirfadlewax-soo-saarka dawooyinka la habeeyey(CMO) iyo R&D dawada la habeeyey iyo adeeg bixiyayaasha wax soo saarka (CDMO).Jindun ayaa ku raaci doona kharashka COVID-19.
Waqtiga boostada: Jan-28-2023